AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 FEB 5 - (NewsRx.com & NewsRx.net) -- Osteoprotegerin levels in women rise to compensate for estrogen deficiency.
According to a study from Japan, "a novel cytokine termed osteoprotegerin (OPG) that is also called osteoclastogenesis-inhibitory factor, which inhibits osteoclast maturation and activity, was recently isolated. In order to determine the influence of estrogen deficiency on the levels of circulating OPG in women, we studied the changes in the levels of circulating OPG in 10 Japanese women ages 25-49 (mean[+ or -]SD, 34.0[+ or -]6.9) years with endometriosis receiving gonadotropin-releasing hormone agonists (GnRH-a) therapy."
"We further analyzed whether the levels of circulating OPG have relations with the levels of the biomarkers of bone turnover or those of circulating mineral components in these patients during GnRH-a treatment. The patients were treated with a monthly injection of 3.75 mg leuprolide acetate depot for 6 months," said H. Uemura and colleagues, University of Tokushima, School of Medicine.
"In all patients, the concentrations of serum estradiol decreased after 6 months of GnRH-a treatment. The bone mineral density of the lumber spines in these patients significantly (p
"The values of circulating OPG also correlated significantly with those of serum calcium (Ca) and phosphorus (P) (r=0.65 and 0.72, p
"These results suggest that circulating OPG levels rise against the increase in osteoblastic bone resorption and circulating Ca levels in the case of estrogen deficiency, possibly as a compensatory mechanism ...
Source: HighBeam Research, Osteoprotegerin levels in women rise to compensate for estrogen...